Miracor Medical Systems GmbH is an Austrian medical device company developing disruptive solutions to treat severe heart diseases; striving to bring back cardiac patients to normal life.
Miracor develops and commercializes the PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function.
PiCSOAMI Therapy seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after an Acute Myocardial Infarction (AMI).
Recent Pre-Clinical and Clinical Studies have successfully demonstrated the positive effects of PiCSO on myocardial function and infarct size in acute heart attack patients.
The CE-marked PiCSO AMI Impulse System consists of a driving console and associated catheters and offers the Heart Team new options to improve clinical outcome in Acute Myocardial Infarction patients.
The company is conducting further post-market clinical trials to further proof the safety and effectiveness of the PiCSOAMI Therapy in heart attack patients undergoing coronary revascularization with percutaneous coronary intervention (PCI-stenting).
First clinical studies showed that also Heart Failure (HF) patients may benefit from even only short periods of PiCSO by improving structural integrity and induction of regenerative pulses.
Based on this, further research activities are currently conducted for the treatment of Heart Failure patients, aiming to reverse the adverse mechanisms of the failing heart with the PiCSOHF Therapy.